EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force

  title={EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force},
  author={Stefan Evers and Judit {\'A}fra and Achim Frese and Peter J. Goadsby and Mattias Linde and Arne May and P. S. Sándor},
  journal={European Journal of Neurology},
Background:  Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients’ quality of life. 

Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study

We sought to assess factors associated with the frequency of self‐reported prescription opioid use in persons with migraine, including demographic variables, comorbidities, headache characteristics,

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

  • Medicine, Psychology
  • 2019
To provide healthcare professionals with updated guidance in the use of novel preventive and acute treatments for migraine in adults.

Safety and efficacy of flunarizine in childhood migraine: 11 years’ experience, with emphasis on its effect in hemiplegic migraine

Aim  The aim of this study was to report a single‐centre experience of flunarizine in childhood migraine with focus on safety and efficacy.

Migraine: New US guidelines for preventive treatment of migraine

In April 2012, the American Academy of Neurology and the American Headache Society issued new guidelines on preventive treatment for episodic migraine, which provide valuable information regarding drug efficacy and address the equally important issue of adverse events.

Negative predictors of clinical response to amitriptyline in Japanese patients with migraine

This presentation explains the development and use of a wide variety of prophylactic drugs for migraine, and some of the properties of these drugs vary greatly among individuals.

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.

The cost of headache disorders in Europe: the Eurolight project

This is the first comprehensive estimation of how economic resources are lost to headache in Europe, and it is hoped that this will help clarify the financial costs of headaches in Europe.

Influence of disease features on adherence to prophylactic migraine medication

Objectives –  Randomized controlled trials of prophylactic treatments for migraine focus on the effects in an ideal situation and underestimate the impact of non‐adherence, which in this study was

Diagnosis and Treatment of Primary Headache Disorders in Older Adults

To provide a unique perspective on geriatric headache and a number of novel treatment options that are not well known outside of the headache literature.

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials

The efficacy of galcanezumab, a monoclonal antibody for migraine prevention, has been demonstrated in two pivotal trials in patients with episodic migraine.



Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: A Randomized, Double‐Blind, Placebo‐Controlled Study

  • P. WinnerD. Lewis On Behalf Of The Rizatriptan Adolescent Study Grou
  • Medicine, Psychology
  • 2002
This study aims to investigate the tolerability and efficacy of rizatriptan 5 mg in adolescent migraineurs and to establish a smoking cessation protocol for this drug.

Within‐Patient Early Versus Delayed Treatment of Migraine Attacks With Almotriptan: The Sooner the Better

This data suggests that earlier use of triptans may be more beneficial than waiting until headache intensity is at least moderate to begin triptan therapy.

Topiramate for Migraine Prevention in Adolescents: A Pooled Analysis of Efficacy and Safety

The efficacy and safety of topiramate for migraine prevention in adolescents from 3 randomized, 26‐week, double‐blind, placebo‐controlled trials is characterized.

Severe Vascular Events in Migraine Patients

Objective.—To estimate rates of vascular events in relation to dispensing of triptans and ergot alkaloids among migraineurs, and to compare these rates with those of nonmigraineurs.

Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.

Efficacy of Rizatriptan 10 mg Administered Early in a Migraine Attack

Objective.—To determine if administration of rizatriptan 10 mg is superior to placebo for the early treatment of acute migraine, while the pain is mild.

Venlafaxine Extended Release (XR) for the Prophylaxis of Migraine and Tension‐type Headache: A Retrospective Study in a Clinical Setting

Assessment of the efficacy of extended‐release venlafaxine in the prophylaxis of migraine and chronic tension‐type headache finds it safe and effective.

Tramadol/Acetaminophen for the Treatment of Acute Migraine Pain: Findings of a Randomized, Placebo‐Controlled Trial

To compare tramadol/acetaminophen (APAP) and placebo for the management of acute migraine pain with real-time data is presented.

Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based Study

Background.— Though symptomatic medication overuse is believed to play a major role in progression from episodic to chronic or transformed migraine (TM), population‐based longitudinal data on these

Almotriptan Improves Response Rates When Treatment Is Within 1 Hour of Migraine Onset

Background.—Results from open‐label trials with almotriptan and sumatriptan have shown higher response rates when treatment was initiated early after acute migraine onset.